The international researcher team discovered the previously unknown function of the Galectin-1 protein in the nuclei of the fibroblast cells forming tumor micro-environment pancreatic cancer. This may be the basis of new strategies to combat one of the most aggressive oncology species. Published in İş Magazine National Academy of Sciences Procedings (PNAs).
Work Coordinator “Micheneral tumor or stroma is a key factor in the aggression of pancreatic cancer. Not only protects tumor cells from the effect of drugs, but also contributes to their growth and distribution, Pilan said.
Previously, it was known that fibroblasts secreted gallectin-1 and increased tumor processes. However, scientists have now shown that the protein is moving within the fibroblasts’ nuclei themselves, and that the key tumor growth genes regulates the expression of genes, including KRAS.
KRAS is a gear that has mutations in 90% of pancreatic cancer cases. It is considered one of the main motors of the malignant degeneration of the cells. The new discovery shows that Galectin-1 can activate epigenetically in these fibroblasts and increase its support for unchanging tumor in DNA.
“This is changing the approach to this treatment,” said Nepov Martinez-Bosh. “We should develop drugs that prevent not only Galectin-1 outside the cage, but also the activity of the fibroblast nucleus.”
The authors emphasize: The results of the study can lead to the development of new effective methods to treat pancreatic cancer, taking into account the complex role of the micro environment and the interaction between tumor cells and healthy cells.
Previously KnownHow obesity changes the brain.